- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
ADAC makes artifact correction gains
ADAC Medical Systems, thenewly created equipment division of ADAC Laboratories, will displayVantage, its simultaneous transmission-emission attenuation correctiontechnique for the Vertex adjustable dual-head gamma camera (SCAN6/1/94). The technique is
ADAC Medical Systems, thenewly created equipment division of ADAC Laboratories, will displayVantage, its simultaneous transmission-emission attenuation correctiontechnique for the Vertex adjustable dual-head gamma camera (SCAN6/1/94). The technique is useful in eliminating artifacts createdduring nuclear cardiology procedures. ADAC has submitted a 510(k)application with the Food and Drug Administration for the techniqueand expects to have marketing clearance by December.
ADAC, of Milpitas, CA, will emphasize the throughput advantagesof using Vantage with the gamma camera detectors in the 90ºconfiguration. This offers higher throughput compared to similartechniques used on triple-head cameras, according to Ian Farmer,vice president of nuclear medicine marketing. Picker, the onlyvendor with a simultaneous attenuation correction technique onthe market, uses the technology on its triple-head Prism 3000camera (SCAN 6/1/94).
ADAC will also display 511-KeV collimators for fluorodeoxyglucose(FDG) imaging with Vertex. ADAC expects the technique to showutility in oncology imaging, Farmer said.
On the radiology information systems side, ADAC HealthcareInformation Systems will highlight its QuadRIS product, introducedearlier this year. ADAC will also show its progress in developingan information system for mammography facilities.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
